BIOCRYST PHARMACEUTICALS INC BCRX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
6/9
Piotroski F — financial health
-2.63
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $874.8M | $263.9M | — | — | -$119.2M |
| 2024 | $450.7M | -$88.9M | — | — | -$475.9M |
| 2023 | $331.4M | -$226.5M | — | — | -$455.5M |
| 2022 | $270.8M | -$247.1M | — | — | -$294.6M |
| 2021 | $157.2M | -$184.1M | — | — | -$107.0M |
| 2020 | $17.8M | -$182.8M | — | — | -$19.3M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Milne Jill C. | director | 2026-06-11 | Grant | 15,294 | — |
| Galson Steven K | director | 2026-06-11 | Grant | 15,294 | — |
| LEVIN ALAN G | director | 2026-06-11 | Grant | 15,294 | — |
| Frank Steven | director | 2026-06-11 | Grant | 15,294 | — |
| SANDERS MACHELLE | director | 2026-06-11 | Grant | 15,294 | — |
| MILANO VINCENT | director | 2026-06-11 | Grant | 15,294 | — |
| Stonehouse Jon P | director | 2026-06-11 | Grant | 15,294 | — |
| McKee Amy E | director | 2026-06-11 | Grant | 15,294 | — |
Why these scores methodology →
Piotroski F-score: 6/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -2.63 (distress)
- Working capital / assets 0.405
- Retained earnings / assets -2.929
- EBIT / assets 0.663
- Equity / liabilities -0.188
Source: SEC EDGAR filings · CIK 0000882796 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.